newsfilter
← Latest News
GlobeNewswire·

NervGen Pharma to Participate at Upcoming Investor Conferences

  • NervGen Pharma Corp. announced that CEO Adam Rogers & executive leadership will present at three upcoming investor conferences.
  • The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, via a virtual corporate presentation & 1x1 meetings.
  • NervGen is scheduled to present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, in Boston, MA, featuring a corporate presentation & 1x1 meetings.
  • The company will participate in the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, FL, through 1x1 investor meetings.
  • Live webcasts & archived replays of the presentations will be available on the investors section of www.nervgen.com.
  • NervGen is developing NVG-291, a subcutaneously administered neuroreparative peptide, which is the first pharmacologic candidate to show durable functional improvement in chronic spinal cord injury patients.
  • The Phase 1b/2a CONNECT SCI Study for subacute spinal cord injury is ongoing, with preparations underway for a Phase 3 trial in chronic SCI.
  • NVG-291 holds Fast Track designation from the FDA & Orphan Drug designation from the European Medicines Agency for spinal cord injury treatment.
  • The company is also advancing NVG-300, a next-generation candidate, to transform treatment paradigms for neurotraumatic & neurologic conditions.